Bundibugyo Virus Disease in 2026 — Clinical and Public Health Responses
New England Journal of Medicine · 16.07.2026 · 395 (3) · 278-289
DOI: 10.1056/nejmra2607216 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift New England Journal of Medicine, erschienen am 16.07.2026. Verfasst von Nancy J Sullivan. Beteiligte Einrichtung: Department of Biology, College of Arts and Sciences, Boston University, Boston. Hauptthemen laut MEDLINE: Disease Outbreaks, Ebolavirus, Hemorrhagic Fever, Ebola, Public Health. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 81 Literaturangaben.
Abstract (Originalsprache)
Bundibugyo virus is a relatively rare orthoebolavirus that has caused only two previously recognized disease outbreaks but remains capable of producing severe epidemic disease with substantial mortality. The 2026 outbreak of Bundibugyo virus disease in the Democratic Republic of Congo has highlighted persistent challenges in the detection of filovirus disease outbreaks, as well as in diagnosis, clinical management, and the public health response, particularly in resource-limited settings. As with other filovirus infections, effective control of the Bundibugyo virus disease outbreak depends on rapid identification of cases, laboratory confirmation of infection, isolation of cases, contact tracing, infection-prevention measures, protection of health care workers, and community engagement. Although no licensed vaccines or approved therapeutics specific to Bundibugyo virus disease are currently available, advances in supportive care have improved outcomes during recent filovirus disease outbreaks. Experimental evidence from studies involving nonhuman primates, serologic investigations with human samples, and monoclonal antibody research suggests that vaccines and therapeutics developed against Ebola virus may provide cross-protective activity against Bundibugyo virus. These observations support prototype-pathogen approaches to preparedness while underscoring the need for continued development of pathogen-specific countermeasures. The current outbreak reinforces the principle that a successful response to filovirus disease requires integration of medical countermeasures, clinical care, surveillance, diagnostics, and coordinated multinational public health operations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biology, College of Arts and Sciences, Boston University, Boston.
- Department of Virology, Immunology, and Microbiology, Chobanian and Avedisian School of Medicine, Boston University, Boston.
Zitieren
APA
Sullivan, N. J. (2026). Bundibugyo Virus Disease in 2026 — Clinical and Public Health Responses. New England Journal of Medicine, 395(3), 278-289. https://doi.org/10.1056/nejmra2607216
Vancouver
Sullivan NJ. Bundibugyo Virus Disease in 2026 — Clinical and Public Health Responses. New England Journal of Medicine. 2026;395(3):278-289. doi:10.1056/nejmra2607216
BibTeX
@article{Sullivan2026,
author = {Sullivan, Nancy J},
title = {Bundibugyo Virus Disease in 2026 — Clinical and Public Health Responses},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {3},
pages = {278--289},
doi = {10.1056/nejmra2607216}
}
EUVIMED